Hemogenyx Pharmaceuticals PLC Announces Feasibility Study Agreement
Each party retains its technology ownership, while the HG-CT-1 Phase I trial remains unaffected by the laboratory study.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Hemogenyx Pharmaceuticals (HOPHF) has signed a feasibility study agreement with Nitto Denko to evaluate delivery of its CAR-encoding messenger RNA to human T cells. The laboratory study will combine Hemogenyx's FLT3-targeting chimeric antigen receptor (CAR) instructions with Nitto's cell-targeted lipid nanoparticles, particles designed to carry those instructions into cells. It is expected to take approximately four months, and each party retains ownership of its technology.
Hemogenyx describes this as its first step toward reprogramming patients' T cells inside the body rather than manufacturing individual cell treatments outside it. The company believes technical success could support an off-the-shelf product that is easier to manufacture, store and distribute. The study is an in vitro evaluation, not a patient trial. The ongoing HG-CT-1 Phase I trial in relapsed/refractory acute myeloid leukemia remains unaffected and the principal focus.
Positive
- Minor pointSigned Nitto Denko agreement advances laboratory evaluation of targeted delivery of Hemogenyx's FLT3-CAR messenger RNA.
- Minor pointTechnology ownership retained by each party under the study agreement.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential off-the-shelf product could simplify manufacturing, storage and distribution, Hemogenyx believes, if technically feasible.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Feasibility remains unproven: the in vitro study is expected to take approximately four months.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, UK / ACCESS Newswire / October 19, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical group announces that it has entered into a Feasibility Study Agreement (the "Agreement") with Nitto Denko Corporation ("Nitto") (TSE:6988), the Japan-based manufacturer of high-performance materials.
Under the Agreement, the parties will evaluate whether Nitto's cell-targeted lipid nanoparticle ("ctLNP") drug delivery technology can deliver Hemogenyx's messenger RNA ("mRNA") encoding its FLT3-targeting chimeric antigen receptor ("CAR") to human T cells (the "Study").
Highlights
- The Study is the Company's first step towards an in vivo CAR-T approach, in which a patient's T cells are reprogrammed inside the body by an injectable medicine rather than engineered individually in a manufacturing facility.
- If the approach proves successful, it could allow Hemogenyx's CAR-T technology to be converted into a drug-like, off-the-shelf product that is significantly easier to manufacture, store and distribute than traditional autologous CAR-T therapy.
- The Study combines Hemogenyx's proprietary FLT3-CAR mRNA with Nitto's ctLNP technology; each party retains ownership of its own technology.
- The Study is an in vitro evaluation, is expected to take approximately four months.
- The Company's ongoing Phase I clinical trial of HG-CT-1 in relapsed/refractory acute myeloid leukemia ("R/R AML") is unaffected and remains its principal focus.
Strategic rationale
HG-CT-1, the Company's lead product candidate, is an autologous CAR-T cell therapy: each dose is made from the individual patient's own T cells, which are collected, genetically engineered and expanded outside the body before being returned to that patient. While autologous CAR-T therapies have transformed the treatment of certain blood cancers, this patient-by-patient manufacturing model is complex, time-consuming and costly, and it limits the number of patients and treatment centers that can be served.
An in vivo approach seeks to remove that constraint. mRNA encoding the CAR is packaged in lipid nanoparticles designed to seek out T cells; once administered, the nanoparticles deliver the mRNA to the patient's T cells, which then produce the CAR themselves. The therapeutic product is therefore not a living, patient-specific cell preparation but a defined pharmaceutical formulation that could, in principle, be manufactured in large batches, held in inventory and administered to any eligible patient without cell collection or a bespoke manufacturing run for each individual. Because mRNA-driven CAR expression is transient, such a product may also allow CAR-T cell activity to be controlled through dosing.
The Company believes that, if technically feasible, an in vivo product built on the Company's FLT3-CAR could materially broaden the reach and commercial potential of Hemogenyx's CAR-T technology, complementing the autologous HG-CT-1 program currently in the clinic.
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"Autologous CAR-T therapy works, but every dose is a bespoke manufacturing campaign for a single patient. In vivo CAR-T offers a fundamentally different model: a drug-like product, made at scale and available off the shelf, that instructs the patient's own T cells to become CAR-T cells inside the body. This Study with Nitto, a recognized leader in nucleic acid medicine and drug delivery, opens that opportunity for Hemogenyx. It allows us to test, at modest cost, whether our FLT3-CAR can be delivered by targeted lipid nanoparticles, and so whether the technology behind HG-CT-1 can be translated into a product that is significantly easier to manufacture and to deliver to patients. Our priority remains the HG-CT-1 Phase I trial; this work runs alongside it and, if successful, could considerably extend the value of our CAR-T platform."
UK Market Abuse Regulation (UK MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
| Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com |
| Peter Redmond, Director | peterredmond2@btinternet.com |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Caroline Rowe |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
About Nitto Denko Corporation
Since its founding in 1918, Nitto has globally provided a wide range of products and services as a high-performance materials manufacturer, including optical materials used in display devices such as smartphones and automotive displays, advanced semiconductor materials, high density printed circuit boards for data centers, medical-related products and services, and decarbonization solutions, based on its core technologies. Under its brand slogan, "Innovation for Customers," Nitto aims to create indispensable value for society and contribute to a sustainable global environment and a prosperous human society.
Forward-looking statements
This announcement contains forward-looking statements, including statements regarding the potential of in vivo CAR-T approaches, the expected conduct, timing and outcome of the Study, and any future relationship between the Company and Nitto. Such statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the inherent uncertainty of early-stage research. The Company undertakes no obligation to update these statements except as required by law or regulation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What will Hemogenyx and Nitto Denko test under their feasibility study agreement?
The study will test whether Nitto's cell-targeted lipid nanoparticles can deliver messenger RNA encoding Hemogenyx's FLT3-targeting chimeric antigen receptor to human T cells. It is an in vitro laboratory evaluation expected to take approximately four months, rather than a clinical trial in patients.
Does Hemogenyx's Nitto study affect the HG-CT-1 clinical trial?
The ongoing HG-CT-1 Phase I trial in relapsed/refractory acute myeloid leukemia is unaffected and remains Hemogenyx's principal focus. The feasibility study runs alongside that clinical program.
Why is Hemogenyx exploring messenger RNA for CAR-T delivery inside the body?
Hemogenyx believes messenger RNA delivery could allow CAR-T activity to be controlled through dosing, because the resulting CAR expression is transient. The approach would instruct patients' T cells inside the body, rather than require cell collection and a separate manufacturing run for each patient.